Skip to content

International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia

Neurological Complications Associated With Serum Sodium ≤110 mmol/L and Its Treatment: An International Multi-Centre Retrospective Study.

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07576036
Acronym
PRONATREOUS
Enrollment
800
Registered
2026-05-08
Start date
2023-11-01
Completion date
2026-06-30
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Edema, Hyponatremia Symptomatic, Osmotic Demyelination Syndrome

Keywords

Treatment and outcome of severe hyponatremia

Brief summary

Electronic medical records dating back as far as available for each center to identify patients admitted to the hospital with a serum sodium ≤110 mmol/l. Data on patient demographics, presenting symptoms, vital signs, laboratory findings, treatment given, sodium correction rates, presence of risk factors for osmotic demyelination syndrome (ODS) and outcomes including suspected and MRI-confirmed ODS, in-hospital death, and imaging confirmation of cerebral edema

Interventions

Rapid Correction of hyponatremia

Sponsors

Rochester General Hospital
Lead SponsorOTHER
University of Pittsburgh Medical Center
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Serum sodium ≤110 mmol/L at admission to the hospital

Exclusion criteria

* Blood glucose \>15 mmol/L, spurious laboratory dataa

Design outcomes

Primary

MeasureTime frameDescription
Osmotic demyelination syndrome1 to 14 daysNeurological deterioration after treatment of hyponatremia
MRI-confirmed Osmotic Demyelination SyndromeWithin 30 daysPost treatment neurological deterioration with CPM and/or EPM

Secondary

MeasureTime frameDescription
Cerebral edema2 daysCerebral edema documented by imaging or death or respiratory arrest from suspected cerebral edema

Countries

United States

Contacts

STUDY_CHAIRRichard H Sterns, MD

University of Rochester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026